Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, March 8, 2018 NEWTOWN, Pa. , March 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
Effect of rigosertib plus azacitidine treatment on epigenetic modulation in cancer cell-lines and patient derived bone marrow cells Study suggests potential novel clinical strategies to improve outcomes for patients with higher-risk Myelodysplastic Syndromes and reversal of resistance to treatment
• Pint Pharma to Make Upfront Investment in Onconova • Onconova also Eligible to Receive up to $42.75 Million in Regulatory and Sales Milestones NEWTOWN, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on
NEWTOWN, Pa. , March 06, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), will present at
NEWTOWN, Pa. , March 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided
NEWTOWN, Pa. , March 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present new data on ON 123300, a
First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of the novel combination therapy in higher risk patients with Myelodysplastic Syndromes (MDS) Study demonstrates elimination of grade 3 or grade 4 urinary adverse events after implementation of
Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300 Preclinical data reveals differential metabolism of ON 123300 in male versus female rodents, with implications for development of dosing strategy Development program is in collaboration with HanX
NEWTOWN, Pa. , April 27, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
Underwriter’s Option to Purchase Additional Securities Exercised in Full NEWTOWN, Pa. , May 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to
NEWTOWN, Pa. , May 03, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that the Company will present
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday May 15, 2018 NEWTOWN, Pa. , May 09, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer,
NEWTOWN, Pa. , May 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced
NEWTOWN, Pa. , June 07, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced a presentation at the